Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background Four direct oral anticoagulants (DOACs) have been brought to market for the
treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background: Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF).
The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF …

Objective Since 2010, several non–vitamin K antagonist oral anticoagulants (NOACs) have
been brought to the US market, yet little is known regarding their evolving adoption for …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Among atrial fibrillation (AF) patients, Danish nationwide registries (2011–2015) were used
to examine temporal trends of initiation patterns of oral anticoagulation (OAC) treatment …

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for
prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF). Increased use of …

Objectives To describe (i) the trend in oral anticoagulant (OAC) use following the
introduction of non-vitamin K antagonist oral anticoagulant (NOAC) therapy for stroke …